Wave Life Sciences heads into its third-quarter report with a striking disconnect. Last quarter management sounded more confident than it had in some time, pointing to an in-person FDA meeting on an accelerated path for its alpha-1 antitrypsin deficiency drug, WVE-006, and live Phase 2a dosing for its obesity candidate, WVE-007. The stock has since fallen 43.6% while the S&P 500 gained 4.1%. That meeting was slated for the end of summer, so the October 27 release, due before the open, is the first scheduled chance for Wave to tell shareholders what came of it.

The income statement will not settle much. Analysts expect a loss of 34 cents a share, matching the prior quarter and slightly wider than the 32-cent loss a year earlier. Revenue is projected at about $3.3 million, down roughly 57% from $7.6 million a year ago, though modestly above last quarter's $2.3 million. For a clinical-stage company without formal financial guidance, collaboration revenue mostly reflects the timing of partner payments rather than business momentum. The figure that matters is cash. Wave ended June with $490.6 million, down from $602.1 million two quarters earlier, and its second-quarter net loss widened to $69.4 million as research and administrative costs both rose. Management's runway into the third quarter of 2028 should hold up, but another step up in spending would raise questions about how much of the 2026 pipeline can be funded before outside capital becomes necessary.

The operational test centers on WVE-006. Over several quarters, management moved from expecting regulatory feedback around mid-year to securing a face-to-face meeting. It also completed dosing across the 200, 400 and 600 milligram cohorts after regaining full rights to the program. A clear readout from that meeting would validate the improved tone. That means agreement on an accelerated approval framework, or at least a defined path with identified endpoints. Vague language, a request for more data or silence would challenge it. Because this was the single biggest positive change in last quarter's story, it carries the most weight now.

Obesity is the second pillar. The Phase 2a InLight study in patients with a body mass index of 35 to 50 was already dosing, and the company said its incretin combination and post-incretin maintenance trials would start in the second half. Confirmation that those studies have begun, along with an on-schedule clinical trial application for the liver program WVE-008, would show that the expanding timetable is being met. Any slippage would land hard on a stock already priced for disappointment. Shareholders should also look for an update on the fall Investor Day and its promised detail on the bifunctional platform.

The soft spot remains Duchenne muscular dystrophy. Management backed away from its long-standing plan to file an NDA for N531 in 2026. It now prefers to find a partner first and to wait for regulatory clarity on a competing therapy. A signed deal would turn a retreat into a source of non-dilutive cash. Continued drift would reinforce the sense that the program has been shelved.

Sentiment has turned from modestly bullish before the last report to modestly bearish now. The shares trade at $3.17, well below the 200-day moving average near $7.98. They sit just above the $3.04 post-earnings low and far beneath the previous quarter's $5.40 to $7.62 range. That leaves a low bar but a fragile one. The question that will decide whether Wave's improving narrative survives is whether management can turn its FDA meeting on WVE-006 into a concrete, credible regulatory path while keeping cash burn in check.